Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit tumor progression and provide a favorable prognosis in clinical practice. Activating mutations of epidermal growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shang-Gin, Shih, Jin-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817870/
https://www.ncbi.nlm.nih.gov/pubmed/29455650
http://dx.doi.org/10.1186/s12943-018-0777-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817870/
https://www.ncbi.nlm.nih.gov/pubmed/29455650
http://dx.doi.org/10.1186/s12943-018-0777-1

Ejemplares similares